Press releases
March 10, 2022
GelMEDIX
This partnership represents the first equity investment of the incubator created by HTL to accelerate the development of innovative treatments using biopolymers in therapeutic areas with unmet medical needs.
HTL will provide financial, industrial and scientific support to GelMEDIX to facilitate the development of next generation ocular and regenerative therapies based on its proprietary hydrogel platform.
This platform enables the delivery of therapeutics from small molecules to cell and gene therapies.
To see our most recent news,
Read more
news from us
-
Articles April 16, 2024HTL Biotechnology at In-cosmetics Global Congress in Paris
As every year, the In-Cosmetics Global Congress returns to Paris, with top industry leaders and experts gathering under one roof.
This event promises opportunities and insights into the future of Cosmetics. -
Articles April 9, 2024France BioLead Membership
France BioLead structures, pilots, supports and promotes the French biomanufacturing sector.
-
Articles March 28, 2024Attending AMWC in Monaco
AMWC, the Aesthetic & Anti-Aging Medicine World Congress in Monaco.